Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why Axovant Sciences Is Soaring 25% Today

What happened

After the company announced that former Medivation CEO David Hung will be its new CEO, shares in Axovant Sciences (NYSE: AXON  ) were 24.5% higher at 1:20 pm EST today.

So what

Axovant's team includes Lawrence Friedhoff, the person behind the development of the multibillion-dollar Alzheimer's disease drug Aricept; now, the company has even more been-there-done-that experience, thanks to hiring Hung.

A businessman sitting on the ground against a wall has money falling from the sky around him.


At Medivation, Hung led the development and commercialization of the multibillion-dollar prostate cancer drug Xtandi. He also orchestrated Pfizer's massive $14 billion acquisition of Medivation last year.

Hung will try to use his experience to usher Axovant's lead drug, intepirdine, to market. Intepirdine is a& 5-HT6-receptor antagonist that boosts the production of acetylcholine, a neurotransmitter important for cognition and brain function. It's currently in phase 3 studies for use alongside Friedhoff's Aricept, a drug that prevents the body from breaking down acetylcholine in patients with mild to moderate Alzheimer's disease.

Now what

Unfortunately, 99% of Alzheimer's disease drugs in trials have failed, and that suggests that Hung faces some steep odds at Axovant. Those odds aren't helped by the fact that other drugmakers, including Pfizer, have attempted to target the 5-HT6 receptor without success.

Fortunately, investors won't have to wait too long to find out if intepirdine's trial pans out; results are expected later this year. If the trial shows that intepirdine can help delay disease progression, there's a very good chance that it will become a blockbuster. Increasingly more people are being diagnosed with Alzheimer's disease, and sadly, there are limited treatment options available.

Undeniably, adding a proven leader in the C-suite is good news for investors. But the failure rate associated with Alzheimer's disease trials makes this stock a risky bet. If intepirdine succeeds where others have failed, there's a big opportunity for profit, but a disappointment could cause this company's shares to crater.

10 stocks we like better than Axovant Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Axovant Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of April 3, 2017

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 4012650, ~/Articles/ArticleHandler.aspx, 4/29/2017 1:28:05 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 4 hours ago Sponsored by:
Change down DOW 20940.5 -40.8 -0.2%
Change down S&P 500 2384.2 -4.6 -0.2%
Change down NASD 6047.6 -1.3 0.0%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

4/28/2017 4:00 PM
AXON $24.24 Down -0.11 -0.45%
Axovant Sciences CAPS Rating: *

Article registration testing

Revisit this page

Clear article's cache and revisit this page

Or, visit the current page, forcing Test ID to article:interrupt:106919 and

Tookie Value = 55115982632179262859129726378062